Nikitakis NG, Georgaki M, Merkourea S, Chaisuparat R, Warburton G, Lopes MA, Papadimitriou JC, Ord RA. Juvenile trabecular ossifying fibroma: Immunohistochemical expression of MDM2, CDK4 and p53 compared to conventional ossifying fibroma. J Clin Exp Dent. 2022;14(1):e27-34.

doi:10.4317/jced.59116

___________

References

1. Kramer IR, Pindborg JJ, Shear M. editors. Histological typing of odontogenic tumors. 2nd ed. Spring-Verlag. Berlin, 1992. p.28. https://doi.org/10.1007/978-3-662-02858-2

2. El-Mofty S. Psammomatoid and trabecular juvenile ossifying fibroma of the craniofacial skeleton: two distinct clinicopathologic entities. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:296-304. https://doi.org/10.1067/moe.2002.121545 PMid:11925539

3. Slootweg PJ. Juvenile trabecular ossifying fibroma: an update. Virchows Arch. 2012;461:699-703. https://doi.org/10.1007/s00428-012-1329-5 PMid:23052375

4. Chrcanovic BR, Gomez RS. Juvenile ossifying fibroma of the jaws and paranasal sinuses: a systematic review of the cases reported in the literature. Int J Oral Maxillofac Surg. 2020;49:28-37.5. https://doi.org/10.1016/j.ijom.2019.06.029 PMid:31285096

5. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and MDM2 alterations in osteosarcomas. Cancer. 1997;79:1541-7. https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y

6. Dujardin F, Binh MB, Bouvier C, Gommez-Brouchet A, Larousserie F, Muret A. et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24:624-37. https://doi.org/10.1038/modpathol.2010.229 PMid:21336260

7. Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M. et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23:1279-88. https://doi.org/10.1038/modpathol.2010.124 PMid:20601938

8. Mejia-Guerrero S, Quejada M, Gokgoz N, Gill M, Parkes R, Wunder JS. et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer. 2010;49:518-25. https://doi.org/10.1002/gcc.20761 PMid:20196171

9. Lopes MA, Nikitakis NG, Ord RA, Sauk J Jr. Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws. Oral Oncol. 2001;37:566-71. https://doi.org/10.1016/S1368-8375(00)00130-5

10. Nikitakis NG, Drachenberg CB, Papadimitriou JC. MDM2 and CDK4 expression in carcinosarcoma of the esophagus: comparison with squamous cell carcinoma and review of the literature. Exp Mol Pathol. 2002;73:198-208. https://doi.org/10.1006/exmp.2002.2465 PMid:12565795

11. El-Mofty SK, Nelson B, Toyosawa S. Ossifying fibroma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds). WHO Classification of Head and Neck Tumours (4th edition). IARC: Lyon, 2017.

12. Johnson LC, Yousefi M, Vinh TN, Heffner DK, Hyams VJ, Hartman KS. Juvenile active ossifying fibroma: its nature, dynamics and origin. Acta Otolaryngol Suppl. 1991;448:1.

13. Zama M, Gallo S, Santecchia L, Bertozzi E, De Stefano C. Juvenile active ossifying fibroma with massive involvement of the mandible. Plast Reconstr Surg. 2004;113:970-4. https://doi.org/10.1097/01.PRS.0000105629.56850.AA PMid:15108891

14. Leimola-Virtanen R, Vähätalo K, Syrjänen S. Juvenile active ossifying fibroma of the mandible: a report of 2 cases. J Oral Maxillofac Surg. 2001;59:439-44. https://doi.org/10.1053/joms.2001.21883 PMid:11289176

15. Slootweg PJ, Panders AK, Koopmans R, Nikkels PG. Juvenile ossifying fibroma. An analysis of 33 cases with emphasis on histopathological aspects. J Oral Pathol Med. 1994;23:385-8. https://doi.org/10.1111/j.1600-0714.1994.tb00081.x PMid:7823298

16. Junior AT, de Abreu Alves F, Pinto CA, Carvalho AL, Kowalski LP, Lopes MA. Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas. Oral Oncol. 2003;39:521-30. https://doi.org/10.1016/S1368-8375(03)00017-4

17. Guérin M, Thariat J, Ouali M, Bouvier C, Decouvelaere AV, Cassagnau E. et al. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification. Hum Pathol. 2016;50:70-8. https://doi.org/10.1016/j.humpath.2015.11.012 PMid:26997440

18. Limbach AL, Lingen MW, McElherne J, Mashek H, Fitzpatrick C, Hyjek E. et al. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma. Head Neck Pathol. 2020;14:889-98. https://doi.org/10.1007/s12105-020-01139-x PMid:32026294 PMCid:PMC7669933

19. Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170:1062-78. https://doi.org/10.1016/j.cell.2017.08.028 PMid:28886379 PMCid:PMC5743327

20. Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199-212. https://doi.org/10.1038/s41418-018-0246-9 PMid:30538286 PMCid:PMC6329812

21. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120:7-10. https://doi.org/10.1016/S0092-8674(04)01252-8

22. Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A. et al. TP53 in Biology and Treatment of Osteosarcoma. Cancers (Basel). 2021;13:4284. https://doi.org/10.3390/cancers13174284 PMid:34503094 PMCid:PMC8428337

23. Jawad SN, Abdullah BH. Proliferative, apoptotic and angiogenic potentials in jaws and long bones osteosarcomas: a comparative immunohistochemical study. J Oral Pathol Med. 2010;39:681-86. https://doi.org/10.1111/j.1600-0714.2010.00923.x PMid:20701666

24. Oliveira P, Nogueira M, Pinto A, Almeida MO. Analysis of p53 expression in osteosarcoma of the jaw: correlation with clinicopathologic and DNA ploidy findings. Hum Pathol. 1997;28:1361-65. https://doi.org/10.1016/S0046-8177(97)90224-0

25. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003;1:1009-16.

26. Kawaguchi K, Oda Y, Sakamoto A, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M. Molecular analysis of p53, MDM2 and H-ras genes in osteosarcoma and malignant fibrous histiocytoma. Mod Pathol. 2002;15:878-88. https://doi.org/10.1097/01.MP.0000024264.48690.EA PMid:12181274

27. Gao X, Leone GW, Wang H. Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res. 2020;148:147-169. https://doi.org/10.1016/bs.acr.2020.02.002 PMid:32723562

28. Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H. et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36:423-31. https://doi.org/10.1097/PAS.0b013e31824230d0 PMid:22301501

29. Chen PC, Yen CC, Hung GY, Pan CC, Chen WM. Gene amplification and tumor grading in parosteal osteosarcoma. J Chin Med Assoc. 2019;82:889-94. https://doi.org/10.1097/JCMA.0000000000000211 PMid:31634336

30. Iwata S, Tatsumi Y, Yonemoto T, Araki A, Itami M, Kamoda H. et al. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma. Oncol Rep. 2021;46:135. https://doi.org/10.3892/or.2021.8086 PMid:34036394

31. Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de Muret A. et al. Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions. Mod Pathol. 2015;28:48-56. https://doi.org/10.1038/modpathol.2014.80 PMid:24925056